Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan ...
November 23 2020 - 9:15AM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to
developing and delivering medicines that make a meaningful
difference to people affected by neurological diseases, today
announced the appointment of Spyros Papapetropoulos, MD, PhD, to
its Board of Directors. Spyros brings more than 20 years of
academic and industry experience with a focus on neurology, and
previously held R&D and scientific leadership roles at Acadia,
Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas
announced the retirement of Ivan Lieberburg, MD, PhD from the
Adamas board.
“I would like to sincerely thank Ivan for his
dedicated service to Adamas since 2004. He played a critical role
through multiple successful NDA submissions and our evolution into
a successful commercial organization. We wish him well,” said David
L. Mahoney, Chairman, Adamas. “We are pleased to have Spyros join
us at this next stage of growth. As a seasoned research and
development leader, he will be an outstanding addition to our
board.”
“Spyros’ extensive experience within
neurodegenerative diseases and movement disorders, along with his
track record of bringing meaningful therapies to market ideally
position him to bring an important perspective to the board. I look
forward to his contributions as we continue to deliver on our
mission for patients and unlock shareholder value,” added Neil F.
McFarlane, CEO.
“I am delighted to join Adamas at this exciting
time in the journey towards being a leading neurology company,”
said Spyros Papapetropoulos. “I very much look forward to being
part of the company’s future growth and continued success.”
Throughout his career, Spyros has led multiple
pharmaceutical development programs resulting in successful
regulatory filings and product launches. Spyros is a
board-certified Neurologist trained in London, UK, and has authored
more than 160 peer-reviewed publications. Additionally, Spyros has
served on various U.S. government and non-profit committees on
healthcare and biomedical research innovation.
About AdamasAt Adamas, our
vision is clear – to deliver innovative medicines that reduce the
burden of neurological diseases on patients, caregivers, and
society. We are a fully integrated company focused on growing a
portfolio of therapies to address a range of neurological diseases.
For more information, please visit www.adamaspharma.com.
Contact:
Media:Sarah MathiesonVice
President, Corporate
Communications510-450-3528smathieson@adamaspharma.com
Investors:Peter VozzoManaging
Director, Westwicke443-213-0505peter.vozzo@westwicke.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024